INFI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Sep 2023 @ 15:59):

Stats
Today's Volume	2.48M
Average Volume	3.98M
Market Cap	726 089
EPS	$0 ( 2024-03-26 )
Next earnings date	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0182
ATR14	$0.00900 (230.77%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-09	Perkins Adelene Q	Buy	768 133	Common Stock
2023-09-12	Perkins Adelene Q	Sell	410 196	Common Stock
2023-09-09	Perkins Adelene Q	Sell	768 133	Restricted Stock Unit
2022-08-02	Peluso Stephane	Buy	14 994	Common Stock
2022-08-02	Peluso Stephane	Sell	50 000	Restricted Stock Unit

INSIDER POWER
-16.52
Last 96 transactions
Buy: 10 433 668 \| Sell: 9 549 867

Volume Correlation

Long: 0.01 (neutral)

Short: 0.15 (neutral)

Signal:(27.787) Neutral

Infinity Pharmaceuticals Correlation

10 Most Positive Correlations
TTOO	0.944
IMPL	0.942
VNET	0.938
AVIR	0.933
EGAN	0.931
STAF	0.924
TUEM	0.924
AZYO	0.921
JD	0.92
BGFV	0.92

10 Most Negative Correlations
TA	-0.959
TYHT	-0.937
SERA	-0.936
SYKE	-0.933
RDUS	-0.927
CPTA	-0.924
XLRN	-0.923
ICON	-0.923
ZGNX	-0.92
PAE	-0.915

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Infinity Pharmaceuticals Correlation - Currency/Commodity

-0.68
( moderate negative )

-0.65
( weak negative )

0.00
( neutral )

0.73
( moderate )

0.11
( neutral )

0.43
( neutral )

Infinity Pharmaceuticals Financials

Annual	2022
Revenue:	$2.59M
Gross Profit:	$1.03M (39.72 %)
EPS:	$-0.480

Q2	2023
Revenue:	$583 000
Gross Profit:	$231 000 (39.62 %)
EPS:	$-0.110

Q1	2023
Revenue:	$731 000
Gross Profit:	$290 000 (39.67 %)
EPS:	$-0.120

Q4	2022
Revenue:	$543 000
Gross Profit:	$216 000 (39.78 %)
EPS:	$-0.0983

Financial Reports:

No articles found.

Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.